focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Not sure I agree with the view it was a brilliant interview. Lacking in substance, felt slightly disingenuous, and was essentially a lot of patting himself on the back.
Brilliant scientist no doubt, and I agree he has achieved a lot with minimal capital, but the guys ego and inability to accept any kind of criticism is striking.
Nothing will change on that front so I guess we just have to hold our nose and accept we are stuck with him as the spokesperson.
Personally I’m quite satisfied to wait and see what develops, but I am also realistic. This is a high risk/high reward stock until it either proves up the science in people or until it receives significant funding via licensing something or gets a significant strategic investment, but let’s be completely honest, $830k from prevail is not going to cut it.
If you have a diversified portfolio of investments then the risks here are more than acceptable when balanced against the potential, but it’s not something you want to bet the farm on. Some people here seem destined to either become millionaires or are on a one way street to the poor house, so far as I can tell.
There are many haters of this company who frequent this board, and there are others who can’t accept the idea that this isn’t a slam dunk of an investment. Some balance wouldn’t go amiss, but neither would some better comms and an updated website from the company.
Even with the placing, $4m is not enough for the next year, including running trials. How much of that cash will be burnt through in the next ‘few’ months whilst we await the first patient?
More money is needed, that is obvious, and we are limited in what can be raised via further placings in the next year without either creating a prospectus or delisting from the main market.
The wording of the RNS suggested the placing was to allow the company to ‘progress to trials’, not specifically fund them. It is therefore not inconceivable that a deal with a partner may still be in the offing.
Some clarification from the company would be welcome, but don’t hold your breath. The science may be great but comms are distinctly lacking, and that is holding us back.
I’m not ‘making it up’ Mr India, I just stated that H2 was what was alleged to have been stated in the placing marketing.
I never got the marketing so cannot verify it, but I have no reason to doubt that Digittt is telling the truth.
Given the repeated failure in the past to meet any dates given by Hemo, I suspect the ‘next few months’ probably does equate to H2 in reality.
Mr I,
‘He has gone into hiding and doesn't even want to help the shareholder by coming out and giving a clear indication of WHEN and WHERE trials will be even though the deal was supposed to have been done with prevail’
When - starting second half of 2024 according to Digittt, who apparently received the placing marketing.
Where - U Penn (I believe this is widely known/accepted)
Can’t see much improvement in the SP until much closer to the start of trials tbh.
Other good news would probably have helped a bit with recovery, but it appears that was all already exhausted prior to placing.
Thanks Haywain
My working assumption is that there was probably an offer, but Vlad and the BOD felt they were being seriously low balled due to a lack of cash runway.
In that scenario he may have simply backed himself to get positive data in initial testing, allowing him the opportunity to hold out for a better deal, at the considerable expense of shareholders by placing and dilution.
I would like to think that as comfortably the largest shareholder (taking his wife’s shares into account), he is acting in what he feels is the best interests of all of us.
Limited scope for further placing in the next year and pharma isn’t cheap, so I hope he has acted wisely otherwise we are likely gonna be grinding to a halt on all fronts.
Haywain,
The school of thought regarding the testing of CBR in a government facility either being largely or entirely funded by the government is very plausible.
Any such arrangement would likely keep drug development costs to a minimum, but I do wonder whether this route would allow its full commercial value being realised in the event it can do even half of what it suggests it could.
Things developed by government have a habit of not making their way to the open markets. Government interest is likely twofold, one as a defence against potential biological weapons, the other against the often called ‘disease x’.
Any success in either of the above arenas would be a huge win for science, but perhaps less so for the shareholder?
However, any significant developments in the potential Alzheimer’s or brain cancer treatments will, I suspect, come entirely from the company purse, therefore may have far larger commercial potential. Funding those developments, in my opinion, has a lot of unanswered questions at this moment.
As someone in the scientific field, I would be interested to hear your thoughts.
I still hold a positive outlook for Hemo and have absolutely no intention to part with any shares, but I accept the risks remain high.
Let’s hope the initial data from CART testing is positive. Things could look very different for shareholders at the end of this year, and that initial data will determine the direction of travel, assuming other unexpected news doesn’t land in the meantime of course.
Just when you think the week couldn’t get worse, I now see Vlad has reactivated his twitter account…
I shouldn’t worry about Tilly, something tells me he will be absolutely fine. After all, the guy was a genius, he somehow always managed to load up on the dips just before any decent raise!
He’s possibly skippering Stu’s yacht somewhere, perhaps through the Bermuda Triangle and never to be seen or heard from again.
I do wonder about Micky though, always felt he was a genuine guy and investor. Absolutely no filter, but he always said it how he saw it. Haven’t seen him here since the placing RNS, but I hope he is doing ok.
Which, BrewHaHa, is exactly why they should have followed after, when the risk of a placing had been removed.
I personally feel that at 4p, the market had more or less priced in the hold being lifted. There’s been some dilution, but the 50% drop is just too much.
It’s likely going to see a lot of churn during March, but I think it will start to see a steady rise at some point as we move closer to needles going into arms.
I still think releasing the two recent CBR RNS’s should have come after placing if they were going to do it at 2p. That would have helped the share price recovery along somewhat.
That being said, it’s ultimately the science that will make or break this, and given the credentials of the scientists at Hemo, for me the risks are very acceptable when measured against the potential.
Not sure I’m in agreement with your 8p valuation there orhy, but I do agree with the sentiment.
Pre clinical hold being lifted this was at 4p. That hurdle is now out the way and with around 12% dilution and a bit of cash runway banked, we have now dropped back to sub 2p.
It was a disappointing raise at a bad price, but I’m not privy to know what alternatives were available. It is what it is, and crying about it now won’t achieve anything. As for the current share price fall back, It’s overdone in my opinion. The coming weeks until the first patient gets treated will be volatile as there is loads of churn to go yet, but I suspect in a few months when trials start, we may be closer to 4p than 2p. For those thinking of offloading in disgust, which would be understandable, I think you will be able to get yourself a better price if you have a bit of patience. That’s only my thoughts anyway, and only time will tell.
Yes, I’m disappointed with where we are today in respect of the share price, but nothing much on the science front has changed, and we are not in bad shape in that regard.
Never mind bait bio, they need to focus on the primary website first and foremost.
There is only one, you can check this via the London Stock Exchange site
Well, even suspecting there might be a raise I didn’t see that coming at 2p. Absolutely shocking price to raise at.
Why on earth did the company bother to release news on CBR prior to placing, only to do it at this price?
If you are going to raise at such a meagre price, then surely it would have been better to release the CBR updates AFTER the raise so as to offer LTH’s a bit of respite in what is now going to be a very volatile period.
Some seriously questionable decisions being made at this company on the business front, I really do hope that the science aspect is eventually going to compensate for this.
I won’t be selling up, but I won’t lie, today’s news is a very big disappointment.
Stu,
I have not seen anyone trying to suggest a dilutive placing to be a really good thing. Disingenuous of you to suggest so, unless of course you can point me to a post that I may have missed.
Obviously better forms of funding do exist, assuming they are available. The point I was making is that no matter what the funding route taken, it is hard to see how the share price falls much further than it has since the hold was lifted.
Let’s wait and see, I intend to be here for quite some time yet.
Mr I,
‘ Apart from CART FDA approval what exactly has he done for shareholders !!! Nothing. ’
You make it sound like anyone can just achieve what he has, which is absolutely laughable by the way.
It’s clear that lots of ‘investors’ here are in fact just gamblers, and have gone way beyond their comfort zone with this share.
Purely playing devils advocate here, but even IF there was a placing, even at 2.5p, the share price would still warrant being higher than it currently is. The company would still be clinical, still have the exact same IP, and would also have a cash runway to begin trials. That scenario would probably see a fair few people sell up in disgust, but for others it would signal a pathway forward and an opportunity to enter with some clarity on how things can begin to move forward. Again, this is completely hypothetical and I am not suggesting this is reality.
As the biggest shareholder in hemo, you have to have some belief that Vlad will do what’s best for the company, and ultimately the share price, even if the way he goes about it is not the way some here would like. As Haywain has mentioned, maybe any deal available to them now is not acceptable to the company.
Anyway, it’s pointless posting here again until there is something official to discuss.
Too many people are constantly fixated on the share price, which leads me to believe they are here for the short term only and will sell on any kind of reasonable lift.
Personally, I am focused on the future of the company and what that can deliver for patients, and then in turn myself (financially) as a byproduct of that. Focusing further down the line allows me to concern myself less with what is happening day to day and allows me to not get caught up in the hysteria that I read here constantly.
Yes, funding is required - we all know that. It will likely be dilutive as most funding is (nothing is free in this life) but the long term outlook for the company (and the share price) remains positive. IN MY OPINION.
A bit more patience and a little bit less knicker wetting would be my advice.
Mr I,
If you are advising Micky to not come back until summer then may I suggest you take your own advice.
Your constant moaning on this board is doing absolutely nothing to support this share.